Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported its Q2 2020 financial results, showing a cash balance of $384.4 million as of June 30, a decrease from $439.0 million at year-end 2019, primarily due to $54.8 million in operational costs.
Operating expenses surged to $50.3 million for Q2, up from $22.7 million in 2019. R&D expenses also rose significantly to $44.7 million, reflecting ongoing Phase 3 clinical trials. Amid challenges from the pandemic, the company is focused on completing enrollment for its MAESTRO trials and received an upgrade to the NASDAQ Global Select Market.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 2020 financial results, stating progress in its Phase 3 studies, MAESTRO-NASH and MAESTRO-NAFLD-1, despite COVID-19 challenges. The company announced a cash position of $408.5 million, down from $439.0 million at the end of 2019, primarily due to operational expenses of $30.5 million. R&D expenses surged to $33.4 million from $12.4 million year-over-year due to trial initiations. Notably, resmetirom showed over 60% reduction in liver fat and a 64% NASH resolution rate. Interest income decreased to $1.9 million.